https://endpts.com/lilly-novos-bet-on-heart-disease-starts-to-take-shape-and-2024-could-be-a-pivotal-year-for-their-glp-1s/
Eli Lilly and Novo Nordisk are steadily — and somewhat quietly — preparing to build comprehensive cardiovascular franchises helmed by their lucrative treatments for diabetes and obesity. This year, the companies have started to publicly talk up their plans to…
Create an account or login to join the discussion